Abstract: This disclosure relates to the identification of a subset of mGluR network gene CNVs that are predictive of efficacy of treatment with fasoracetam, as well as the identification of an mGluR network gene CNV that is predictive of an increased likelihood of having ADHD as well as having certain symptoms associated with ADHD.

Abstract: The present disclosure relates to methods of treating ulcerative colitis with anti-LIGHT antibodies. The disclosure also relates to assaying free LIGHT prior to, during, or after administration of an anti-LIGHT antibody to treat ulcerative colitis.

Abstract: The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.

Abstract: The present disclosure relates to methods of treating subjects with complex lymphatic malformations, comprising administering to a human subject diagnosed with a complex lymphatic malformation an effective amount of trans-4-[4-Amino-5-(7-methoxyl-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazine-7-yl]-cyclohexanecarboxylic acid, or a pharmaceutically acceptable salt thereof at certain dosages.

Abstract: The present disclosure relates to methods of treating adult-onset Still’s disease (AOSD) or systemic-onset juvenile idiopathic arthritis (SoJIA), optionally associated with elevated IL-18 levels, comprising administering to a human subject diagnosed with AOSD or SoJIA an effective amount of an anti-IL-18 antibody at certain dosages.

Abstract: The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.

Abstract: The present disclosure relates to methods of treating and/or detecting respiratory and inflammatory conditions associated with IL-18 by administering an anti-IL-18 antibody, optionally wherein the antibody comprises the six CDRs of SEQ ID NOS: 122, 123, 124, 126, 127, and 128, wherein 122-124 comprise the heavy chain CDRs and 126-128 comprise the light chain CDRs, to subjects aving elevated IL-18 levels. Conditions include acute respiratory distress syndrome (ARDS) and hemophagocytic lymphohistiocytosis HLH)/Macrophage activation syndrome (MAS), optionally wherein the ARDS and HLH/MAS are associated with viral infection, including coronavirus infection.

Abstract: This disclosure relates to the identification of a subset of mGluR network gene CNVs that are predictive of efficacy of treatment with fasoracetam, as well as the identification of an mGluR network gene CNV that is predictive of an increased likelihood of having ADHD as well as having certain symptoms associated with ADHD.

Abstract: The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.

Abstract: This disclosure relates to the identification of a subset of mGluR network gene CNVs that are predictive of efficacy of treatment with fasoracetam, as well as the identification of an mGluR network gene CNV that is predictive of an increased likelihood of having ADHD as well as having certain symptoms associated with ADHD.

Abstract: Micro-organ compositions and methods of implanting into the central nervous system (CNS) for the treatment of CNS-related diseases are encompassed. Specifically, the disclosure provides methods for treating disorders including cancer and lysosomal storage diseases, the methods comprising implanting a micro-organ into the CNS, wherein the micro-organ secretes a recombinant protein, and wherein the micro-organ is maintained in the CNS, and secretes protein, for at least seven days.

Abstract: Provided herein is a genetically-modified micro-organ that provides a sustained delivery of a therapeutic peptide. The genetically-modified micro-organ may comprise a viral vector or expression cassette comprising at least two nucleic acid sequences encoding the therapeutic peptide separated by a cleavable linker. Further provided herein is a method of treating or preventing a disease or disorder in a human subject that can be treated or prevented by administration of a therapeutic peptide over a sustained time period using the genetically-modified micro-organ described herein.